Don’t be surprised to see pharma seek to change the US patent reform debate

Washington DC is in mid-term election mode and, as it’s not clear how the battle for control of the Senate will play out, speculating on what is going to be on the next Congress’s agenda might be regarded as a little foolish. So, I thought I’d give…